Effect of hypolipidemic drugs on key enzyme activities related to lipid metabolism in normolipidemic rabbits

European Journal of Pharmacology

Volumn 347, Issue 2-3, 1998, Pages 283-291

  Alegret, Marta ^a   Verd, Joan C ^a   Díaz, Cristina ^b   Hernández, Gonzalo ^b   Adzet, Tomás ^a   Sánchez, Rosa M ^a   Laguna, Juan C ^a  

^a U de Farmacol y Farmacognosia   (Spain)

^b Departamento I + D   (Spain)

Author keywords

Atorvastatin; Bezafibrate; Cholesterol 7 hydroxylase; CTP:phosphocholine cytidylyl transferase; Normolipidemic rabbit; Simvastatin

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; BEZAFIBRATE; CHOLESTEROL 7ALPHA MONOOXYGENASE; CHOLESTEROL ACYLTRANSFERASE; CHOLINE PHOSPHATE CYTIDYLYLTRANSFERASE; DIACYLGLYCEROL ACYLTRANSFERASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; LIPID; LIPOPROTEIN LIPASE; LIVER TRIACYLGLYCEROL LIPASE; SIMVASTATIN; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; ENZYME INHIBITION; LIPID BLOOD LEVEL; LIPID METABOLISM; LIVER MICROSOME; MALE; NONHUMAN; PHOSPHOLIPID SYNTHESIS; PRIORITY JOURNAL; RABBIT; TRIACYLGLYCEROL BLOOD LEVEL;

ACYLTRANSFERASES; ANIMALS; ANTILIPEMIC AGENTS; BEZAFIBRATE; CHOLESTEROL; DIACYLGLYCEROL O-ACYLTRANSFERASE; HEPTANOIC ACIDS; HYDROXYMETHYLGLUTARYL COA REDUCTASES; LIPIDS; LIVER; MALE; PHOSPHOLIPIDS; PYRROLES; RABBITS; SIMVASTATIN; TRIGLYCERIDES;

EID: 0032562494     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(98)00096-X     Document Type: Article

References (58)

1. Alegret M., Ferrando R., Vázquez M., Adzet T., Merlos M., Laguna J.C. Relationship between plasma lipids and palmitoyl-CoA hydrolase and synthetase activities with peroxisomal proliferation in rats treated with fibrates. Br. J. Pharmacol. 112:1994;551-556.
2. Benhizia F., Lagrange D., Malewiak M.I., Griglio S. In vivo regulation of hepatic lipase activity and mRNA levels by diets which modify cholesterol influx to the liver. Biochim. Biophys. Acta. 1211:1994;181-188.
3. Bertolotti M., Abate N., Loria P., Dilengite M., Carubbi F., Pinetti A., Digrisolo A., Carulli N. Regulation of bile acid synthesis in humans: effect of treatment with bile acids, cholestiramine or simvastatin on cholesterol 7α-hydroxylation rates in vivo. Hepatology. 14:1991;830-837.
4. Bertolotti M., Concari M., Loria P., Abate M., Pinetti A., Guicciardi M.E., Carulli N. Effects of different phenotypes of hyperlipoproteinemia and of treatment with fibric acid derivatives on the rates of cholesterol 7α-hydroxylation in humans. Arterioscler. Thromb. Vasc. Biol. 15:1995;1064-1069.
5. Bjorkhem I., Berglund L. Stimulatory effect of mevilonin on rat liver phosphatidic acid phosphatase. Biochim. Biophys. Acta. 920:1987;20-25.
6. Boggs K.P., Rock C.O., Jackowski S. Lysophosphatidylcholine and 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine inhibit the CDP-choline pathway of phosphatidylcholine synthesis at the CTP:phosphocholine cytidylyl transferase step. J. Biol. Chem. 270:1995;7757-7764.
7. Bradford M. A rapid sensitive method for the quantitation of microgram quantities of protein utilizing the principles of protein-dye binding. Anal. Biochem. 72:1976;248-254.
8. Coleman R.A. Diacylglycerol acyltransferase and monoacylglycerol acyltransferase from liver and intestine. Meth. Enzymol. 209:1992;98-101.
9. Chao Y., Chen J.S., Hunt V.M., Kuron G.W., Karkas J.D., Liou R., Alberts A.W. Lowering of plasma cholesterol levels in animals by lovastatin and simvastatin. Eur. J. Clin. Pharmacol. 40(Suppl. 1):1991;S11-14.
10. Desager J.-P., Horsmans Y. Clinical pharmacokinetics of 3-hydroxy-3-methylglutaryl-Coenzyme A reductase inhibitors. Clin. Pharmacokinet. 31:1996;348-371.
11. Dostal L.A., Whitfield L.R., Anderson J.A. Fertility and general reproduction studies in rats with the HMG-CoA reductase inhibitor, atorvastatin. Fundam. Appl. Toxicol. 32:1996;285-292.
12. Endo A. The discovery and development of HMG-CoA reductase inhibitors. J. Lipid Res. 33:1992;1569-1582.
13. Glaser D.S., Yost T.J., Eckel R.H. Preheparin lipoprotein lipolytic activities: relationship to plasma lipoproteins and postheparin lipolytic activities. J. Lipid Res. 33:1992;209-214.
14. Goa K.L., Barradell L.B., Plosker G.L. Bezafibrate. An update of its pharmacology and use in the management of dyslipidemia. Drugs. 52:1996;725-753.
15. Goldberg R., La Belle P., Zupkis R., Ronca P. Comparison of the effects of lovastatin and gemfibrozil on lipids and glucose control in non-insulin-dependent diabetes mellitus. Am. J. Cardiol. 66:1990;16B-21B.
16. Havel R.J., Rapaport E. Management of primary hyperlipidemia. N. Eng. J. Med. 332:1995;1491-1498.
17. Helgerud P., Saarem K., Norum K.R. Acyl-CoA:cholesterol acyltransferase in human small intestine: its activity and some properties of the enzymic reaction. J. Lipid Res. 22:1981;271-277.
18. Hong C.Y., Lin S.J., Chang M.S., Chiang B.N., Shen P.M., Shiao M.S. Effect of pravastatin on fatty acid profile of low density lipoprotein in patients with hypercholesterolemia. Prostaglandins, Leukotrienes and Essential Fatty Acids. 48:1993;155-158.
19. Humble E., Al-Shurbaji A., Lund E., Berglund L. Studies on rat liver phosphatidate phosphohydrolase and plasma lipids: effect of HMG-CoA reductase inhibitors. Biochim. Biophys. Acta. 1214:1994;32-38.
20. Ishida F., Sato A., Iizuka Y., Kitani K., Sawasaki Y., Kamei T. Effects of MK-733 (simvastatin), an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase on intestinal acylcoenzyme A:cholesterol acyltransferase activity in rabbits. Biochim. Biophys. Acta. 1004:1989;117-123.
21. Kawashima Y., Keiichi M., Kozuka H. Peroxisome proliferators enhance linoleic acid metabolism in rat liver. Increased biosynthesis of omega-6-polyunsaturated fatty acids. J. Biol. Chem. 265:1990;9170-9175.
22. Khan B.V., Fungwe T.V., Wilcox H.G., Heimberg M. Cholesterol is required for the secretion of the very-low-density lipoprotein: in vivo studies. Biochim. Biophys. Acta. 1044:1990;297-304.
23. Klosiewicz-Latoszek L., Szostak W.B. Comparative studies on the influence of different fibrates on serum lipoproteins in endogenous hyperlipoproteinaemia. Eur. J. Clin. Pharmacol. 40:1991;33-41.
24. Lake B.G., Gray T.J.B. Species differences in hepatic peroxisome proliferation. Biochem. Soc. Trans. 13:1985;859-861.
25. Lamb R.G., Koch J.C., Bush S.R. An enzymatic explanation of the differential effects of oleate and gemfibrozil on cultured hepatocyte triacylglycerol and phosphatidylcholine biosynthesis and secretion. Biochim. Biophys. Acta. 1165:1993;299-305.
26. Larsen M.L., Illingworth R. Drug treatment of dyslipoproteinemia. Med. Clin. North Am. 78:1994;225-245.
27. Lea A.P., McTavish D. Atorvastatin. A review of its pharmacology and therapeutic potential in the management of hyperlipidemias. Drugs. 53:1997;828-847.
28. Leiss O., Meyer-Krahmer K., von Bergmann K. Biliary lipid secretion in patients with heterozygous familial hypercholesterolemia and combined hyperlipidemia. Influence of bezafibrate and fenofibrate. J. Lipid Res. 27:1986;213-223.
29. Linscheer W.G., Atreyee B., Uma K.M., John W., Sandor N., Jyotirmoy N. Lovastatin induces synthesis of cholesterol, which acts as a secretagogue of biliary phospholipids in rats. Am. J. Physiol. 268:1995;G242-G250.
30. Montgomery M.R., Cinti D.L. Pyridine nucleotide-dependent electron transport in kidney cortex microsomes: interaction between desaturase and other mixed function oxidases. Mol. Pharmacol. 13:1977;60-69.
31. Nakandakare E., Garcia R.C., Rocha J.C., Sperotto G., Oliveira H.C.F., Quintao E.C.R. Effects of simvastatin, bezafibrate and gemfibrozil on the quantity and composition of plasma lipoproteins. Atherosclerosis. 85:1990;211-217.
32. Owens D., Collins P., Johnson A., Tighe O., Robinson K., Tomkin G.H. Hypercholesterolemia: simvastatin and pravastatin alter cholesterol metabolism by different mechanisms. Biochim. Biophys. Acta. 1082:1991;303-309.
33. Plosker G.L., McTavish D. Simvastatin. A reappraisal of its pharmacology and therapeutic efficacy in hypercholesterolemia. Drugs. 50:1995;334-363.
34. Qin W., Infante J., Wang S.-R., Infante R. Regulation of HMG-CoA reductase, apoprotein-B and LDL receptor gene expression by the hypocholesterolemic drugs simvastatin and ciprofibrate in HepG2, human and rat hepatocytes. Biochim. Biophys. Acta. 1127:1992;57-66.
35. ánchez et al., 1992.
36. Sánchez R.M., Viñals M., Alegret M., Vázquez M., Adzet T., Merlos M., Laguna J.C. Inhibition of rat liver microsomal fatty acid chain elongation by gemfibrozil in vitro. FEBS Lett. 300:1992;89-92.
37. Sato A., Watanabe K., Fukuzumi H., Hase K., Ishida F., Kamei T. Effect of simvastatin (MK-733) on plasma triacylglycerol levels in rats. Biochem. Pharmacol. 41:1991;1163-1172.
38. Schoonjans K., Staels B., Auwerx J. Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. J. Lipid Res. 37:1996;907-925.
39. Shand J.H., West D.W. The effects of simvastatin and cholestyramine, alone and in combination, on hepatic cholesterol metabolism in the male rats. Lipids. 30:1995;917-926.
40. Shapiro D.J., Nordstrom J.L., Mitschelen J.J., Rodwell V.W., Schimke R.T. Microassay for 3-hydroxy-3-methylglutaryl-CoA reductase in rat liver and in L-cell fibroblasts. Biochim. Biophys. Acta. 370:1974;369-377.
41. Shefer S., Cheng F.W., Hauser S., Batta A.K., Salen G. Regulation of bile acid synthesis. Measurement of cholesterol 7α-hydroxylase activity in rat liver microsomal preparations in the absence of endogenous cholesterol. J. Lipid Res. 22:1981;532-536.
42. Simsolo R., Ong J.N., Kern P.A. Effect of gemfibrozil on adipose tissue and muscle lipoprotein lipase. Metabolism. 42:1993;1486-1491.
43. Staels B., Auwerx J. Perturbation of developmental gene expression in rat liver by fibric acid derivatives: lipoprotein lipase and alpha-fetoprotein as models. Development. 115:1992;1035-1043.
44. Stahlberg D., Angelin B., Einarsson K. Effects of treatment with clofibrate, bezafibrate and ciprofibrate on the metabolism of cholesterol in rat liver microsomes. J. Lipid Res. 30:1989;953-958.
45. Stahlberg D., Reihnér E., Ewerth S., Einarsson K., Angelin B. Effects of bezafibrate on hepatic cholesterol metabolism. Eur. J. Clin. Pharmacol. 40:1991;S33-S36.
46. Stahlberg D., Reihnér E., Rudling M., Berglund L., Einarsson K., Angelin B. Influence of bezafibrate on hepatic cholesterol metabolism in gallstone patients: reduced activity of cholesterol 7α-hydroxylase. Hepatology. 21:1995;1025-1030.
47. Stange E.F., Fruhholz M., Osenbrugge M., Reimann F., Ditschuneit H. Bezafibrate fails to directly modulate HMG-CoA reductase or LDL catabolism in human mononuclear cells. Eur. J. Clin. Pharmacol. 40(Suppl. 1):1991;S37-40.
48. Tikkanen M.J., Ojala J.-P., Helve E. Lovastatin and gemfibrozil in the treatment of type 2a and type 2b hyperlipoproteinemia. Eur. J. Clin. Pharmacol. 40:1991;S23-S25.
49. ère et al., 1994.
50. Tronchère H., Record M., Tercé F., Chap H. Phosphatidylcholine cycle and regulation of phosphatidylcholine biosynthesis by enzyme translocation. Biochim. Biophys. Acta. 1212:1994;137-151.
51. Vance D. Phosphatidylcholine metabolism: masochistic enzymology, metabolic regulation and lipoprotein assembly. Biochem. Cell Biol. 68:1990;1151-1165.
52. Vessby B., Lithell H. Interruption of long-term lipid-lowering treatment with bezafibrate in hypertriglyceridaemic patients. Atherosclerosis. 82:1990;137-143.
53. ó et al., 1986.
54. Vilaró S., Reina M., Ramírez I., Llobera M. Intralipid administration induces a lipoprotein lipase-like activity in the livers of starved adult rats. Biochem. J. 236:1986;273-278.
55. Vlahcevic Z.R., Heuman D.M., Hylemon P.B. Regulation of bile acid synthesis. Hepatology. 13:1991;590-600.
56. Weinhold P.A., Feldman D.A. Choline-phosphate cytidylyltransferase. Methods Enzymol. 209:1992;248-258.
57. Weisweiler P. Simvastatin and bezafibrate: effect on serum lipoproteins and lecithin:cholesterol acyltransferase activity in familial hypercholesterolaemia. Eur. J. Clin. Pharmacol. 35:1988;579-583.
58. Yanagita T., Yamamoto K., Ishida S., Sonda K., Morito F., Saku K., Sakai T. Effects of simvastatin, a cholesterol synthesis inhibitor on phosphatidyl choline synthesis in HepG2 cells. Clin. Ther. 16:1994;200-208.